Article Type
Changed
Thu, 01/10/2019 - 13:20
Display Headline
Printable Guide on the Rosacea Patient Journey
Article PDF
Author and Disclosure Information

 

Sandy Kuo, MD; Karen E. Huang, MS; Scott A. Davis, MA; Steven R. Feldman, MD, PhD

From the Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, North Carolina. Dr. Feldman also is from the Departments of Pathology and Public Health Sciences.

The Center for Dermatology Research is supported by an unrestricted educational grant from Galderma Laboratories, LP. Dr. Kuo, Ms. Huang, and Mr. Davis report no conflict of interest. Dr. Feldman is a speaker for Janssen Biotech, Inc, and Taro Pharmaceuticals USA, Inc, and a consultant for Amgen Inc; Baxter; HanAll BioPharma Co, Ltd; Kikaku America International; Merck & Co, Inc; Merz Inc; Mylan Inc; Novartis Corporation; Pfizer Inc; and XenoPort, Inc. He also is a consultant and speaker for Abbott Laboratories; Eli Lilly and Company; Galderma Laboratories, LP; LEO Pharma; and Stiefel, a GSK company. Dr. Feldman also has received grants from Abbott Laboratories; Amgen Inc; Anacor Pharmaceuticals, Inc; Celgene Corporation; Galderma Laboratories, LP; Janssen Biotech, Inc; and Stiefel, a GSK company. He also is on the advisory board for Pfizer Inc, and is a founder and stockholder for Causa Research.


Correspondence: Karen E. Huang, MS, Department of Dermatology, Wake Forest School of Medicine, Medical Center Blvd, Winston-Salem, NC 27157-1071 (kehuang@wakehealth.edu).

Issue
Cutis - 95(1)
Publications
Topics
Page Number
37-43
Legacy Keywords
patient experience, diagnosis, treatment, compliance, management, quality of life
Sections
Author and Disclosure Information

 

Sandy Kuo, MD; Karen E. Huang, MS; Scott A. Davis, MA; Steven R. Feldman, MD, PhD

From the Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, North Carolina. Dr. Feldman also is from the Departments of Pathology and Public Health Sciences.

The Center for Dermatology Research is supported by an unrestricted educational grant from Galderma Laboratories, LP. Dr. Kuo, Ms. Huang, and Mr. Davis report no conflict of interest. Dr. Feldman is a speaker for Janssen Biotech, Inc, and Taro Pharmaceuticals USA, Inc, and a consultant for Amgen Inc; Baxter; HanAll BioPharma Co, Ltd; Kikaku America International; Merck & Co, Inc; Merz Inc; Mylan Inc; Novartis Corporation; Pfizer Inc; and XenoPort, Inc. He also is a consultant and speaker for Abbott Laboratories; Eli Lilly and Company; Galderma Laboratories, LP; LEO Pharma; and Stiefel, a GSK company. Dr. Feldman also has received grants from Abbott Laboratories; Amgen Inc; Anacor Pharmaceuticals, Inc; Celgene Corporation; Galderma Laboratories, LP; Janssen Biotech, Inc; and Stiefel, a GSK company. He also is on the advisory board for Pfizer Inc, and is a founder and stockholder for Causa Research.


Correspondence: Karen E. Huang, MS, Department of Dermatology, Wake Forest School of Medicine, Medical Center Blvd, Winston-Salem, NC 27157-1071 (kehuang@wakehealth.edu).

Author and Disclosure Information

 

Sandy Kuo, MD; Karen E. Huang, MS; Scott A. Davis, MA; Steven R. Feldman, MD, PhD

From the Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, North Carolina. Dr. Feldman also is from the Departments of Pathology and Public Health Sciences.

The Center for Dermatology Research is supported by an unrestricted educational grant from Galderma Laboratories, LP. Dr. Kuo, Ms. Huang, and Mr. Davis report no conflict of interest. Dr. Feldman is a speaker for Janssen Biotech, Inc, and Taro Pharmaceuticals USA, Inc, and a consultant for Amgen Inc; Baxter; HanAll BioPharma Co, Ltd; Kikaku America International; Merck & Co, Inc; Merz Inc; Mylan Inc; Novartis Corporation; Pfizer Inc; and XenoPort, Inc. He also is a consultant and speaker for Abbott Laboratories; Eli Lilly and Company; Galderma Laboratories, LP; LEO Pharma; and Stiefel, a GSK company. Dr. Feldman also has received grants from Abbott Laboratories; Amgen Inc; Anacor Pharmaceuticals, Inc; Celgene Corporation; Galderma Laboratories, LP; Janssen Biotech, Inc; and Stiefel, a GSK company. He also is on the advisory board for Pfizer Inc, and is a founder and stockholder for Causa Research.


Correspondence: Karen E. Huang, MS, Department of Dermatology, Wake Forest School of Medicine, Medical Center Blvd, Winston-Salem, NC 27157-1071 (kehuang@wakehealth.edu).

Article PDF
Article PDF
Related Articles
Issue
Cutis - 95(1)
Issue
Cutis - 95(1)
Page Number
37-43
Page Number
37-43
Publications
Publications
Topics
Article Type
Display Headline
Printable Guide on the Rosacea Patient Journey
Display Headline
Printable Guide on the Rosacea Patient Journey
Legacy Keywords
patient experience, diagnosis, treatment, compliance, management, quality of life
Legacy Keywords
patient experience, diagnosis, treatment, compliance, management, quality of life
Sections
Disallow All Ads
Article PDF Media